+49%

est. 2Y upside i

FinTechSeries A

Neobank for African migrants in Europe

Rank

#1356

Sector

Fintech

Est. Liquidity

~7Y

Data Quality

Data: Low

Moneco is a high-risk, early-stage bet valued at $5.8M (analyst estimate) with only $3.3M in total funding — after accounting for the $3.3M liquidation preference, common equity represents just ~$2.5M of that value today.

Last updated: May 5, 2026

Bull (15%)+280%

Moneco scales to $5M+ ARR by 2028, attracts a strategic acquirer or raises a Series A at a $35-40M valuation driven by viral growth within African diaspora corridors. Employee equity appreciates ~280% before dilution, supported by a potential pan-African fintech partnership or white-label expansion beyond the Xpollens relationship.

Base (50%)+70%

Moneco reaches $3-4M ARR and closes a follow-on round at a $15-18M valuation, but 20-25% dilution from new capital reduces net equity gains to roughly 70%. Illiquidity on a 2-year horizon means this upside is notional rather than realizable without a near-term exit.

Bear (35%)-80%

Moneco fails to differentiate against Revolut and Wise, regulatory costs mount, and a down round or wind-down follows. With $3.3M in liquidation preference against a $5.8M analyst estimate, common stockholders recover little to nothing, implying roughly an 80% loss of equity value.

Est. time to liquidity~7.0 years

Preference Stack Risk

severe

Funding Intensity

57%

$3.3M in liquidation preferences against a $5.8M valuation means preferred investors are made whole first, leaving only ~$2.5M (~43% of total value) available to common stockholders in any exit at or near today's price.

Dilution Risk

high

With just $3.3M raised to date, Moneco will require multiple additional funding rounds to reach scale, each likely diluting existing common shareholders by 20-30% per round before any liquidity event.

Secondary Liquidity

none

No secondary market exists for equity in a 24-person, $5.8M-valued neobank; any return is entirely contingent on a future M&A transaction or IPO, realistically 6-8 years out.

Questions to Ask at the Interview

Strategic questions based on Moneco's data — designed to show you've done your homework.

  • 1

    “What is your current MoM revenue growth rate, and what specific metrics trigger your next fundraising round?”

  • 2

    “How dependent is the core business model on Xpollens as your EMI license partner, and what is your contingency plan if that relationship changes?”

  • 3

    “What is the employee equity vesting schedule, strike price, and when was the last 409A valuation completed — and does the company have a secondary liquidity or tender offer policy?”

Community

Valuation Sentiment

Our model estimates +49% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.